市場調査レポート

商品コード

1722314

予測的発症前検査の市場規模、シェア、成長分析、検査タイプ別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Predictive Presymptomatic Testing Market Size, Share, and Growth Analysis, By Test Type, By Technology, By Application, By End User, By Region, And Segment Forecast, 2025-2032

出版日: 2025年05月06日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 769,984円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 900,736円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,031,488円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.28円

全表示
概要
目次

概要

サンプル依頼リストに入れる

予測的発症前検査の世界市場規模は2023年に49億米ドルで、予測期間（2025-2032年）のCAGRは9.3%で、2024年の53億6,000万米ドルから2032年には109億1,000万米ドルに成長すると予測されています。

ヘルスケアテクノロジー分野は、疾病の早期発見に対する関心の高まりと予測ツールの進歩に後押しされ、大きな成長を遂げています。早期発見の利点に対する認識の高まりと、より正確で手ごろな検査方法の開発により、これらのソリューションは患者と医療提供者の双方にとって魅力的なものとなっています。資金援助や政策イニシアチブを通じた政府や民間組織からの支援は、技術革新と採用の環境をさらに強化します。しかし、特に中低所得国での高コストや、データのプライバシーや倫理に関する懸念といった障壁が課題となっています。ゲノミクスとバイオインフォマティクスの絶え間ない革新は、精密医療への注目とともに、大きな成長機会を開きます。ハードルを克服し、市場の長期的な持続可能性を確保するためには、利害関係者間の協力が不可欠です。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Veracyte, Inc.
Abbott
23andMe, Inc.
PharmaMar
Quest Diagnostics Incorporated
Celerion
Myriad Genetics, Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Genomic Health
Caris Life Sciences
Natera, Inc.
F. Hoffmann-La Roche
Exact Sciences Corporation
BioAxis DNA Research Centre Private Limited
Color Genomics, Inc.
Direct Laboratory Services LLC（DirectLabs）
Gene Ltd.
Pathway Genomics Corporation
Positive Bioscience, Inc.

結論と提言

Product Code: SQMIG35J2127

Global Predictive Presymptomatic Testing market was valued at USD 4.9 Billion in 2023 and is expected to grow from USD 5.36 Billion in 2024 to USD 10.91 Billion by 2032, with a CAGR of 9.3% during the forecast period (2025-2032).

The healthcare technology sector is experiencing significant growth, fueled by rising interest in early disease detection and advancements in predictive tools. Increased awareness of the benefits of early detection, coupled with the development of more accurate and affordable testing methods, makes these solutions appealing to both patients and healthcare providers. Support from government and private organizations through funding and policy initiatives further enhances the environment for innovation and adoption. However, barriers such as high costs, especially in low- and middle-income countries, and concerns over data privacy and ethics pose challenges. Continuous innovation in genomics and bioinformatics, along with a focus on precision medicine, opens up substantial growth opportunities. Collaborative efforts among stakeholders will be crucial for overcoming hurdles and ensuring the long-term sustainability of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Predictive Presymptomatic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Predictive Presymptomatic Testing Market Segments Analysis

The global predictive presymptomatic testing market is segmented into test type, technology, application, end user, and region. By test type, the market is classified into genetic testing, biomarker testing, family history assessment, and polygenic risk score. Depending on technology, it is divided into next-generation sequencing, microarray analysis, sanger sequencing, and PCR-based testing. According to application, the market is categorized into oncology, cardiology, neurology, and rare genetic disorders. Based on End User, the market is segmented into hospitals, diagnostic laboratories, research institutions, and home testing kits. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Driver of the Global Predictive Presymptomatic Testing Market

The increasing prevalence of chronic noncommunicable diseases (NCDs) like cancer, diabetes, and cardiovascular ailments is fueling the demand for presymptomatic predictive testing. According to the World Health Organization (WHO), NCDs account for a staggering 74% of global deaths, with a significant 86% of these preventable fatalities occurring in low- and middle-income countries. Forecasts from countries such as England and India indicate a dramatic rise in disease incidence, highlighting the critical importance of early detection in improving health outcomes and alleviating the pressures on healthcare systems. This growing urgency underscores the necessity for advanced predictive testing solutions on a global scale.

Restraints in the Global Predictive Presymptomatic Testing Market

Despite significant advancements that have driven genome sequencing costs below USD 100, the high overall expenses associated with performing next-generation sequencing (NGS) assays, ranging from USD 5,000 to USD 7,000, remain a formidable barrier. This challenge is exacerbated by limited reimbursement policies, particularly in low- and middle-income countries. The World Health Organization emphasizes the importance of equitable access to healthcare as a means to reduce disparities globally. Consequently, these financial limitations impede the widespread adoption of presymptomatic testing technologies, highlighting the urgent need for improved funding and policy support to facilitate access and drive market growth.

Market Trends of the Global Predictive Presymptomatic Testing Market

The Global Predictive Presymptomatic Testing market is experiencing a significant surge, driven by the convergence of genomics and digital health technologies. In the short term, governments and healthcare organizations prioritize the integration of genetic testing with digital platforms, enhancing patient care through precision medicine initiatives like the European Union's Horizon Europe. This investment fosters the development of digital solutions that facilitate seamless data sharing and remote monitoring, ultimately enabling personalized health coaching and disease prevention. As a result, predictive presymptomatic testing becomes increasingly convenient and accessible, catering to a growing demand for proactive health management and tailored healthcare solutions globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree Of Competition
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2023
Pestel Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Study
Technology Analysis
Regulatory Landscape

Global Predictive Presymptomatic Testing Market Size by Test Type & CAGR (2025-2032)

Market Overview
Genetic Testing
Biomarker Testing
Family History Assessment
Polygenic Risk Score

Global Predictive Presymptomatic Testing Market Size by Technology & CAGR (2025-2032)

Market Overview
Next-Generation Sequencing
Microarray Analysis
Sanger Sequencing
PCR-Based Testing

Global Predictive Presymptomatic Testing Market Size by Application & CAGR (2025-2032)

Market Overview
Oncology
Cardiology
Neurology
Rare Genetic Disorders

Global Predictive Presymptomatic Testing Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Diagnostic Laboratories
Research Institutions
Home Testing Kits

Global Predictive Presymptomatic Testing Market Size & CAGR (2025-2032)

North America (Test Type, Technology, Application, End User)
- US
- Canada
Europe (Test Type, Technology, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Test Type, Technology, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Test Type, Technology, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Test Type, Technology, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Veracyte, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
23andMe, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PharmaMar
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celerion
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genomic Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAxis DNA Research Centre Private Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Color Genomics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Direct Laboratory Services LLC (DirectLabs)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gene Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pathway Genomics Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Positive Bioscience, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

予測的発症前検査の市場規模、シェア、成長分析、検査タイプ別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Predictive Presymptomatic Testing Market Size, Share, and Growth Analysis, By Test Type, By Technology, By Application, By End User, By Region, And Segment Forecast, 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

予測的発症前検査市場規模：検査タイプ別& CAGR（2025-2032）

予測的発症前検査市場規模：技術別& CAGR（2025-2032）

予測的発症前検査市場規模：用途別& CAGR（2025-2032）

予測的発症前検査市場規模：エンドユーザー別& CAGR（2025-2032）

予測的発症前検査市場規模：地域別& CAGR（2025-2032）